Biogen Company - Search Videos

Company | Biogen

Company | Biogen

Neuroscientist and Associate Director, Biogen

Neuroscientist and Associate Director, Biogen

How Biogen Makes Money: A Focus on Neurological Disorders

How Biogen Makes Money: A Focus on Neurological Disorders

investopedia.com

From Science to Impact with Biogen CEO Chris Viehbacher

From Science to Impact with Biogen CEO Chris Viehbacher

CNBCBecky Quick

How new is the new Biogen? The company's CEO Christopher Viehbacher sat down with STAT's Matthew Herper to discuss the future of Biogen and why they are not "in the Twinkie business.” Read: https://trib.al/Aw9FhJZ #STATSummit | STAT

How new is the new Biogen? The company's CEO Christopher Viehbacher sat down with STAT's Matthew Herper to discuss the future of Biogen and why they are not "in the Twinkie business.” Read: https://trib.al/Aw9FhJZ #STATSummit | STAT

195 viewsOct 28, 2023

Analyst on what Biogen's Alzheimer's drug means for the company

Analyst on what Biogen's Alzheimer's drug means for the company

Biogen CEO Sees New Chapter in Fight Against Alzheimer's

Biogen CEO Sees New Chapter in Fight Against Alzheimer's

Bloomberg.comJohn Tozzi

Clinical Trials | Biogen

Today represents continued progress in Biogen's commitment to Alzheimer's patients. Click here to get the latest Biogen update and learn more about the U.S. FDA’s approval. | Biogen

6.8K viewsJun 7, 2021

Fighting lupus takes innovation. We’re developing potential options to tackle the complexities of this autoimmune disease. | Biogen

4.2K views6 months ago

Biogen shares soar following promising Alzheimer's drug findings

Shares of Biogen soared more than 40% after a surprise successful trial of its experimental Alzheimer's drug. https://reut.rs/3riqFv7 | Reuters

645.4K viewsSep 28, 2022

FacebookReuters

Biogen gets FDA approval for Alzheimer's treatment

120.1K viewsJun 8, 2021

YahooYahoo Finance Video

We’re evolving and diversifying our pipeline. Learn about our focus in immunology, neurology and rare disease. | Biogen

7.3K views7 months ago

Biogen reopens following FDA approval of company's Alzheimer drug

As 2024 wraps up, we’re reflecting on all that we’ve accomplished and how our teams around the world continue to make an impact. From innovating science to supporting their local communities, we’re proud to be Team Biogen. | Biogen

324 viewsDec 30, 2024

Biogen CEO on FDA approval for its Alzheimer's drug

Samsung in Talks to Buy Alzheimer’s Drug Maker for $42 Billion: Report

360 viewsDec 30, 2021

We are pioneers in neuroscience. We are Biogen.

2.6K viewsNov 26, 2019

Biogen to buy rare-disease drugmaker Reata in $7.3B deal

117K viewsJul 28, 2023

YahooYahoo Finance Video

We’re committed to helping Multiple Sclerosis (MS) and Spinal Muscular Atrophy (SMA) patients continue to have access to prescribed Biogen medicines. Our US Patient Services team is working diligently to connect patients and caregivers with the appropriate support. | Biogen

23K viewsJul 14, 2020

What makes Biogen special? Our people and the culture we build together. We’re grounded in continual improvement, deep care for one another, and a shared commitment to making a meaningful impact. See more of what it means to work at Biogen: ow.ly/ZUey50Yccxw Video description: A video showing different adult employees engaging in office activities. | Biogen

343 views2 months ago

Biogen expanding to keep pace with modernization, artificial intelligence

washingtonexaminer.com

Biogen stock rises on Q1 results, Alzheimer's drug sales

13.6K viewsApr 24, 2024

YahooYahoo Finance Video

Biogen cuts the price tag on its Alzheimer's drug in half

288.9K viewsDec 20, 2021

YahooYahoo News Video

Careers | Biogen

Biogen | LinkedIn

Stories | Biogen

Biogen buys Apellis for $5.6B to expand kidney drugs

Amyotrophic lateral sclerosis | Biogen

See more